First Turn Management »

Cytokinetics shares owned by First Turn Management

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by First Turn Management from 13F filings

Historical chart of First Turn Management investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by First Turn Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by First Turn Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $67M 807k 83.49

More positions owned by First Turn Management

Cytokinetics Com New (CYTK)
Cymabay Therapeutics
Vertex Pharmaceuticals Incorporated (VRTX)
Argenx Se Sponsored Adr (ARGX)
Xenon Pharmaceuticals (XENE)
Krystal Biotech (KRYS)
Legend Biotech Corp Sponsored Ads (LEGN)
Karuna Therapeutics Ord
Transmedics Group (TMDX)
Insulet Corporation (PODD)
Day One Biopharmaceuticals I (DAWN)
Mirum Pharmaceuticals (MIRM)
Verona Pharma Sponsored Ads (VRNA)
Dex (DXCM)
Axsome Therapeutics (AXSM)

View all positions for First Turn Management

Top funds holding Cytokinetics

Vanguard Group
Wellington Management Company
Caption Management
T. Rowe Price Associates
Henderson Group
Boxer Capital
Citadel Advisors
Partner Fund Management
Logos Global Management
Lord, Abbett & Co
Millennium Management
Artal Group
Barclays
Gts Securities
Goldman Sachs Group

View all funds holding Cytokinetics